Phaseline

Companies › Solve Therapeutics

Solve Therapeutics: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SLV-324–Phase 1Metastatic Solid TumorsMay 2027
SLV-154–Phase 1Advanced CancerAug 2027
SLR-108
Antibody-radionuclide conjugate for PET imaging
–Phase 1Metastatic Solid TumorsJan 2028
SLX-1411
Non-radiolabeled antibody
–Phase 1Metastatic Solid TumorsJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07108114SLV-324Phase 1Metastatic Solid TumorsOncologyMay 2027
NCT06771219SLV-154Phase 1Advanced CancerOncologyAug 2027
NCT07728942SLR-108Phase 1Metastatic Solid TumorsOncologyJan 2028
NCT07728942SLX-1411Phase 1Metastatic Solid TumorsOncologyJan 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.